ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function
Valerie DicentaiD, Zoi LaspaiD, David SchaaleiD, Manuel SigleiD, Alp BayrakiD, Tatsiana CastoriD, Thanigaimalai PillaiyariD, Stefan LauferiD, Meinrad GawaziD, Anne‐Katrin RohlfingiD
Abstract
BackgroundPlatelet receptors ACKR3 and CXCR4 play a crucial role in a variety of cardio-vascular diseases. Like most chemokine receptors, CXCR4 is a G protein coupled receptor that induces platelet activation. In contrast, the atypical chemokine receptor 3 (ACKR3) lacks the ability to activate heterotrimeric G proteins and its activation leads to platelet inhibition and attenuates thrombus formation. In nucleated cells, heterodimerization of ACKR3 with CXCR4 regulates CXCL12-dependent signaling. The aim of our study was to investigate the formation of ACKR3/CXCR4 heterodimers in platelets and the subsequent consequences for platelet function. Methods and resultsUsing a microscopy proximity ligation assay (PLA, Duolink(R)) to screen for CXCR4/ACKR3 heterodimerization inducing compounds, we found that ACKR3 agonism but not conventional platelet agonists or endogen ligands lead to heterodimer formation. To further characterize the formation of ACKR3/CXCR4 heterodimers, we studied the CXCL12-dependent platelet activation via CXCR4. Both, CXCL12-dependent platelet aggregation and collagen-dependent ex vivo thrombus formation were significantly downregulated by ACKR3 agonism. Moreover, platelet intracellular calcium and Akt signaling were increased by CXCL12 and again suppressed by ACKR3-specific agonists. Previously, CXCL12 was shown to decrease platelet cAMP levels via CXCR4. Treatment with a specific ACKR3 agonist counteracted this CXCL12/CXCR4-dependent cAMP decrease. ConclusionOur results reveal that the formation of platelet ACKR3/CXCR4 heterodimers is dependent on ACKR3 rather than CXCR4. Furthermore, ACKR3 agonism induced heterodimerization is associated with mitigating CXCL12/CXCR4-dependent platelet activation possibly by modulating CXCR4-dependent G protein signaling. Our results indicate possible ACKR3 agonist functions and reinforce the potential therapeutic applications of ACKR3 agonists. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=151 SRC="FIGDIR/small/593491v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@15a8b22org.highwire.dtl.DTLVardef@1647a63org.highwire.dtl.DTLVardef@19f36d1org.highwire.dtl.DTLVardef@1c80776_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstract:C_FLOATNO CXCR4/ACKR3 heterodimerization in platelets. C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 7
- FWCI
- 1.24
- Field percentile
- top 18%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Elevated conformational dynamics makes ACKR3 activation-prone and G protein-incompetent
Kai Wang, Tony Ngo, … Irina Kufareva·bioRxiv·May 20, 2026
- Hemin-induced platelet activation is regulated via ACKR3 chemokine surface receptor - implications for passivation of vulnerable atherosclerotic plaque
Zoi Laspa, Valerie Dicenta, … Meinrad Paul Gawaz·FEBS JournalPeer-reviewed·Oct 10, 2024
- Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies
Claudia V. Perez Almeria, Omolade Otun, … Martine J. Smit·Nature CommunicationsPeer-reviewed·Dec 2, 2025
- Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed by Single-Molecule Analysis of their Conformational Landscapes
C. T. Schafer, R. F. Pauszek, … D. P. Millar·bioRxiv·Oct 31, 2023
- Pro-inflammatory chemokines CCL5, CXCL12, and CX3CL1 bind to and activate platelet integrin αIIbβ3 in an allosteric manner.
Y. K. Takada, M. Fujita, y. takada·bioRxiv·Sep 1, 2022
- Inhibition of constitutive activity of the atypical chemokine receptor ACKR3 by the small-molecule inverse agonist VUF16840
Reggie Bosma, Desislava N. Nesheva, … Rob Leurs·Molecular PharmacologyPeer-reviewed·Oct 26, 2025